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1  |  SARS- ­COV-­2­AND­COVID-­19
Early in December 2019 reports of a pneumonia- like illness of un-
known etiology began to emerge in Wuhan City, Hubei province, 
China. The cause was rapidly identified as a novel coronavirus, ini-
tially named 2019- nCoV, belonging to the genus betacoronavirus, 
which includes the SARS- CoV and MERS- CoV viruses that cause 
severe acute respiratory syndrome (SARS) and Middle East respi-
ratory syndrome (MERS) respectively.1 Phylogenetic analysis of 
the virus demonstrated that it shared 79% sequence identity with 
SARS- CoV 2 and therefore while it was closely related it was indeed 
a distinct virus, which was named by the International Committee on 
Taxonomy of Virus as SARS- CoV- 2. The World Health Organisation 
(WHO) subsequently named the disease caused by SARS- CoV- 2 as 
COVID- 19 on February 11, 2020. The virus spread rapidly and by 
March 11, 2020 the World Health Organisation declared a global 
pandemic. At the time of writing ( April 26, 2021) there have been 
greater than 147m cases of COVID- 19 and more than 3.1m deaths 
worldwide.
The severity of COVID19 ranges from asymptomatic infection, 
through mild flu- like symptoms, to severe COVID19 that can rapidly 
progress to respiratory distress requiring intensive care treatment 
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Summary
The COVID- 19 pandemic rapidly spread around the world following the first reports 
in Wuhan City, China in late 2019. The disease, caused by the novel SARS- CoV- 2 virus, 
is primarily a respiratory condition that can affect numerous other bodily systems in-
cluding the cardiovascular and gastrointestinal systems. The disease ranges in sever-
ity from asymptomatic through to severe acute respiratory distress requiring intensive 
care treatment and mechanical ventilation, which can lead to respiratory failure and 
death. It has rapidly become evident that COVID- 19 patients can develop features of 
interstitial pulmonary fibrosis, which in many cases persist for as long as we have thus 
far been able to follow the patients. Many questions remain about how such fibrotic 
changes occur within the lung of COVID- 19 patients, whether the changes will persist 
long term or are capable of resolving, and whether post- COVID- 19 pulmonary fibrosis 
has the potential to become progressive, as in other fibrotic lung diseases. This review 
brings together our existing knowledge on both COVID- 19 and pulmonary fibrosis, 
with a particular focus on lung epithelial cells and fibroblasts, in order to discuss com-
mon pathways and processes that may be implicated as we try to answer these impor-
tant questions in the months and years to come.
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and mechanical ventilation and can ultimately result in respiratory 
failure and death. Recent studies have shown that the infection 
fatality rate (IFR) from COVID- 19 varies substantially across geo-
graphical locations, which may reflect the variation in population 
age.3,4 Increased age is a major contributing factor to mortality from 
COVID- 19.3,5 Furthermore, increased age is associated with higher 
risk of hospitalization following COVID19 infection.6 In addition 
to increased age, various other factors are now well documented 
to increase risk of death from COVID- 19 including gender (males 
have higher mortality), ethnicity, obesity, and pre- existing medical 
conditions including diabetes, chronic respiratory, cardiac and liver 
diseases, reduced kidney function, hematological malignancies, and 
neurological diseases.7
2  |  PATHOGENESIS­OF­COVID-­19
Although COVID- 19 affects multiple organ systems including the 
cardiovascular and gastrointestinal systems, the respiratory sys-
tem is the primary site of SARS- CoV- 2 pathology.8 SARS- CoV- 2 
is transmitted through respiratory droplets and aerosols and is 
likely initially received by the epithelium of the nasopharynx in 
the first instance, where active viral replication occurs early in the 
course of the disease.9 As the disease progresses, infection of lung 
epithelium occurs. The transmission of virus from the nasophar-
ynx to the lung epithelium is supported by data showing that viral 
load peaks much earlier in throat swabs than in sputum samples; 
viral load likely peaks around the time of symptom onset in throat 
swabs but after onset of symptoms in sputum.9 Crucially, higher 
sputum viral loads and prolonged viral shedding in the lungs are 
associated with COVID- 19 severity,10,11 suggesting that more ef-
ficient transmission of the virus from the upper respiratory tract 
(URT) to the lower respiratory tract (LRT) may contribute to the 
severity of symptoms.
In the immediate search for a cellular receptor that mediates 
SARS- CoV- 2 viral entry, much work focused upon angiotensin con-
verting enzyme 2 (ACE2), which has been shown to mediate SARS- 
CoV viral entry 12- 15 and is highly expressed in the nasal epithelium.14 
Single cell RNA sequencing (scRNAseq) has shown that ACE2 is dif-
ferentially expressed within the respiratory tract with high levels in 
the nasal epithelium, the initial site of infection, lower expression in 
the tracheal and bronchial epithelium, and only 1.2% of alveolar type 
2 epithelial (AT2) cells expressing ACE2 transcripts.16 The receptor 
binding domain (RBD) of SARS- CoV- 2 is found within the S1 sub-
unit of the spike protein.17 While sequence alignment studies have 
shown 76% similarity between SARS- CoV and SARS- CoV- 2, the S1 
protein is not well conserved with only 64% identity between the 
two viruses, which may explain the significant difference in trans-
missibility between the two viruses 18 through as yet undefined co- 
receptors. Following binding of the RBD to ACE2, the S1 protein is 
primed by proteolytic cleavage mediated by transmembrane prote-
ase serine 2 (TMPRSS2), 14 which facilitates fusion of the viral and 
cell membranes to allow viral entry.
In addition to ACE2, numerous other putative receptors for 
viral entry have been suggested including Cathepsin L1, CD147 
and GRP78.19 Crucially, recent studies have highlighted a number 
of novel receptors that can bind SARS- CoV- 2 including integrins 
αvβ3 and αvβ6,20 low- density lipoprotein receptor class A domain 
containing 3 (LDLRAD3) and C- type lectin domain family 4 mem-
ber G (CLEC4G).21 The pathological consequences of SARS- CoV- 2 
binding to such receptors in vivo are yet to be confirmed, however, 
viral entry to proteins other than ACE2 may help to explain (a) the 
difference in transmissibility and disease severity between SARS- 
CoV and SARS- CoV- 2, and (b) the multi- organ nature of COVID- 19 
pathology.
Within the lungs COVID- 19 infection can be broadly divided into 
three main phases: an early infection phase involving viral replica-
tion and relatively mild symptoms; a second pulmonary phase char-
acterized by stimulation of adaptive immunity and predominance of 
respiratory dysfunction as a result of lung injury and hypoxemia, and 
finally in patients who develop the most severe disease, a third sys-
temic hyperinflammation phase.22 In these patients, direct viral in-
jury, uncontrolled cytokine release, and microvascular inflammation 
can combine to cause multi- organ failure, acute respiratory distress 
syndrome (ARDS), hemorrhage/coagulopathy, and secondary bacte-
rial infections.23- 25
Histologically, patients with COVID- 19 present with three main 
patterns: (i) epithelial with reactive epithelial changes and diffuse 
alveolar damage (DAD); (ii) vascular with microvascular damage, 
(micro)thrombi, and acute fibrinous and organizing pneumonia and 
(iii) fibrotic with evidence of interstitial fibrosis. The epithelial and 
vascular patterns may present alone, simultaneously or consecu-
tively in all stages of symptomatic COVID- 19 with epithelial damage 
and vasculopathy characteristic of the early infection while fibrotic 
changes occur later, generally 3 weeks after symptoms.26 Two 
distinct patterns of fatal COVID19 disease with differing clinical 
courses have been suggested: one characterized by high viral load 
and high cytokine expression in the lungs but limited morphological 
changes and a second characterized by low viral load and cytokine 
expression but elevated numbers of immune cells (including CD8+ T 
cells and macrophages), which correlate with the presence of DAD.27
As the global COVID- 19 pandemic has progressed, a large num-
ber of patients have reported a range of symptoms persisting be-
yond the period of acute infection and illness. A range of studies 
have identified persistent fatigue in 60% and breathlessness in 
40% of people up to 3 months following discharge from hospital. 28 
Early lung function and radiology assessments are consistent with 
impaired pulmonary perfusion, alveolar scarring consistent with re-
spiratory problems including fibrotic lung disease, bronchiectasis, 
and pulmonary vascular disease.29 Much of the evidence for these 
possible sequelae are derived from the early data in COVID- 19 pa-
tients along with extrapolation of data from previous SARS and 
MERS outbreaks and patients with ARDS.30- 33 However, a recent 
systematic review has shown that approximately 20% of COVID- 19 
patients had evidence of fibrotic sequelae that persisted at 1- year 
follow- up,34 suggesting that fibrotic changes did not resolve over 
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this time period. Furthermore, approximately 45% of COVID- 19 pa-
tients had impaired diffusing capacity for carbon monoxide (DLC) 
at follow- up.34 The presence of ongoing symptoms in COVID- 19 
patients has been termed long COVID or post- COVID- 19 syndrome 
and although prospective studies are required in order to fully eval-
uate the population morbidity and consequences of these clinical 
manifestations, given the high case volume worldwide they pose a 
growing and significant health concern.
3  |  CURRENT­UNDERSTANDING­OF­
PULMONARY­FIBROSIS
Pulmonary fibrosis is characterized by excessive extracellular ma-
trix (ECM) deposition within the lung interstitium and destruction 
of the normal parenchymal structure leading to progressive loss of 
pulmonary function. It is a key feature of a variety of interstitial 
lung diseases (ILDs) of which idiopathic pulmonary fibrosis (IPF) is 
the most severe and has the worst mortality. IPF is a progressive, 
incurable disease with survival rates worse than most cancers.35 
Treatment options are limited to two clinically approved drugs, 
Nintedanib (Ofev) and pirfenidone (Esbriet), both of which slow 
progression but do not halt or reverse the fibrosis.36- 39 Ultimately, 
the vast majority of IPF patients succumb to respiratory failure and 
death.40
In recent years, great advances have been made in our under-
standing of the underlying pathogenesis of pulmonary fibrosis. A 
combination of genetic, environmental and aging factors is involved 
in the initiation of the fibrotic processes, which likely begins many 
years before clinical manifestations become apparent.41 Genome- 
wide studies have highlighted numerous genes associated with 
the development of IPF including MUC5B, TERT, FAM13A, DSP and 
AKAP13 among others.42- 44 Recent evidence shows that over 17% of 
non- familial IPF cases in the over 65s can be attributed to a known 
genetic susceptibility variant 45,46 Furthermore, genetic variants in 
genes associated with telomere length or surfactant function have 
been found in cases of familial pulmonary fibrosis.47,48 Environmental 
factors including smoking, dust inhalation and asbestos exposure are 
also associated with increased risk of IPF,46 which on a backdrop of 
genetic susceptibility, contribute to IPF development. Infection, par-
ticularly from viruses, has also been postulated to contribute to the 
development of pulmonary fibrosis and with acute exacerbations of 
the disease.49
The pathogenesis of pulmonary fibrosis involves repeated mi-
croinjury to the alveolar epithelium that leads to an aberrant and 
ineffective repair response and epithelial dysfunction, which results 
in the transdifferentiation, activation and expansion of fibroblasts/
myofibroblasts (reviewed in 50 ). Physiological repair of injured al-
veolar epithelial cells is facilitated by signals from underlying (myo)
fibroblasts.51 Once the wound is effectively repaired myofibroblasts 
numbers dramatically reduce through a combination of apoptosis, 
senescence and reverse differentiation.52 The failure to terminate 
the wound- healing response once the injury has been effectively 
repaired is characteristic of fibrosis and leads to the excessive pro-
duction and deposition of ECM proteins by myofibroblasts.53 In ad-
dition, changes in the balance between matrix metalloproteinases 
(MMPs) and tissue inhibitors of MMPS (TIMPs) which ordinarily 
tightly regulate collagen turnover, enhanced extracellular matrix 
(ECM) crosslinking, and changes in immune cell numbers and pheno-
type can all contribute to alterations in the interstitial ECM structure 
and composition in pulmonary fibrosis.54- 58 Parenchymal fibrosis 
leads to stiffening of the lung tissue,59 which dramatically impairs 
lung function by restricting total lung capacity and forced vital ca-
pacity.60 Crucially, stiffening of the lung tissue perpetuates the fi-
brotic response.59,61- 63
While changes to the structure and mechanical properties of the 
matrix drive lung fibrosis and contribute to its progressive nature, 
the two key cell types involved in the initiation of fibrogenesis are 
the alveolar epithelial cells and fibroblasts. Here we will discuss the 
relative contributions of each cell type to the pathogenesis in more 
detail.
4  |  EPITHELIAL­CELLS: ­THE­INITIATOR
The alveolar epithelium is comprised of type I and type II pneumo-
cytes otherwise known as alveolar epithelial cells (ATI and ATII, re-
spectively). ATI cells are thin, squamous cells that form the alveolar 
structures and are the site of gas exchange. ATII cells are cuboidal 
and more numerous than ATI cells, however, are significantly smaller 
in size. They contain large numbers of lamellar bodies and are re-
sponsible for the production and secretion of surfactant, which is 
critical to normal lung function. Furthermore, ATII cells, unlike ATI 
cells, are capable of proliferating and differentiating in to ATI cells, 
and act as progenitor cells during repair of damage to the alveolar 
epithelium.64
The alveolar epithelium is the site of initial injury early in the 
pathogenesis of IPF and it is thought that the loss of ATII cells, which 
is evident in IPF,65 is critical as loss of ATII cells can initiate fibrogen-
esis.66,67 The injury initiates dramatic changes within the alveolar ep-
ithelium; the regenerative capacity of ATII cells, which during normal 
repair proliferate and differentiate in to ATI cells to restore alveolar 
integrity,68 is lost and cells acquire markers of airway epithelial cells 
in a process termed bronchiolarization,69 and the damaged alveolar 
epithelium undergoes apoptosis.70,71 Furthermore, there is emerging 
evidence that ATII cell senescence contributes to IPF pathogenesis.67
In response to the injury, the alveolar epithelium releases a di-
verse array of soluble mediators, inflammatory cytokines and pro- 
remodeling factors that have been implicated in the pathogenesis 
of IPF. Most notably epithelial cells can activate the potently pro- 
fibrotic cytokine, transforming growth factor- β, which is crucial 
to the pathogenesis of pulmonary fibrosis,53 through cell surface 
integrins, including αvβ6 integrins.72,73 Once activated, TGFβ acts 
upon the underlying mesenchyme to stimulate fibrogenesis (for 
more details see subsequent section).53 Additionally, TGFβ upreg-
ulates expression of αvβ6 integrins as part of a positive feedback 
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loop that promotes progressive fibrogenesis.74,75 Furthermore, al-
terations in pathways that impact epithelial cell activation of TGFβ 
can lead to the development of spontaneous age- related lung fi-
brosis in vivo.76
In addition to TGFβ, the damaged alveolar epithelium releases 
numerous other soluble factors known to be involved in pulmo-
nary fibrosis. Increased platelet derived growth factor (PDGF) re-
lease from the epithelium has been described 77 and inhibition of 
PDGF signaling with receptor tyrosine kinase inhibitors or blocking 
antibodies reduces experimental lung fibrosis.78,79 Crucially, one of 
the two clinically approved drugs for IPF, Nintedanib, acts in part 
through inhibition of PDGF signaling. Connective tissue growth 
factor (CTGF) is an additional growth factor that is released by ATII 
cells in IPF,80 the blockade of which can reduce radiation- induced 
lung fibrosis.81 Furthermore, overexpression of CTGF is sufficient 
to induce a transient fibrotic response in the rat lung.82 ATII cells 
also secrete a milieu of inflammatory cytokines. Interluekin- 6 (IL6), 
a key pro- inflammatory cytokine, is released from ATII cells and its 
expression is increased in the hyperplastic alveolar epithelium in pul-
monary fibrosis.83 Furthermore, blockade of IL6 signalling in an in 
vivo mouse model abrogates pulmonary fibrosis.84
5  |  FIBROBLASTS: ­THE­EFFECTOR
Lung fibroblasts play a pivotal role in the development and progres-
sion of lung fibrogenesis. The reside in relatively small numbers 
within the normal lung interstitium, however, in response to injury 
become activated to mediate wound repair. During normal wound- 
healing responses, fibroblasts proliferate and transdifferentiate 
in to contractile, matrix producing myofibroblasts in order to con-
struct new ECM to support new cells and contract the wound, after 
which the cells apoptose to resolve the wound- healing response.85 
However, in pathological fibrosis the repair response does not re-
solve, myofibroblasts persist and continue to deposit matrix proteins 
within the lung interstitium.86
In the context of lung fibrosis, fibroblasts are primarily activated 
through their close interaction with the injured alveolar epithelium. 
The vast array of secreted proteins from the injured epithelium has 
profound effects upon the underlying mesenchymal cell population. 
TGFβ, activated by the alveolar epithelium in response to injury, 
causes fibroblast proliferation,87,88 transdifferentiation to a con-
tractile myofibroblast phenotype,89- 92 and induces the production 
and deposition of ECM proteins.87,93 Overexpression of TGFβ in vivo 
drives fibroblast proliferation, myofibroblast transdifferentiation 
and progressive lung fibrosis,94 highlighting the crucial role of TGFβ- 
mediated effects on fibroblasts in IPF. Importantly, contraction of 
myofibroblasts can result in TGFβ activation further perpetuating 
pro- fibrotic signals.95
Growth factors released by the injured alveolar epithelium im-
pact fibroblast pro- fibrotic responses and contribute to the devel-
opment and progression of pulmonary fibrosis. PDGF is a potent 
mitogen for lung fibroblasts 79,96,97 and blockade of PDGF signaling, 
specifically that mediated through PDGF receptor- beta, can reduce 
lung fibrosis in an experimental bleomycin mouse model.79 Similarly, 
CTGF stimulates fibroblast proliferation,81,98 migration,99 and also 
increases collagen production.100
Pro- fibrotic responses of fibroblasts are also profoundly influ-
enced by inflammatory cytokines. Interleukin- 1 (IL1) overexpression 
in vivo initiates a dramatic pro- inflammatory state indicative of acute 
lung injury (ALI) that results in severe, progressive pulmonary fibro-
sis.101 IL6 acts as a mitogen for fibroblasts isolated from fibrotic lung 
tissue 102 and Wnt1- inducible signaling protein 1 (WISP1)- induced 
fibroblast proliferation is mediated by IL6.103 Moreover, IL6 can re-
duce apoptosis in fibrotic lung fibroblasts.104 Interleukin- 11 (IL11) 
contributes to fibroblasts transdifferentiation in to myofibroblasts 
and stimulates collagen production via an extracellular signal- 
regulated kinase (ERK)- dependent pathway.105 Interleukin- 25 (IL25) 
enhances fibroblasts proliferation and production of collagens, 
and augments the release of CTGF from alveolar epithelial cells.106 
Additionally, the Th17 cytokine interleukin- 17 (IL17) also increases 
fibroblast proliferation and collagen production.107 While the rel-
ative role of inflammation in the development and progression of 
pulmonary fibrosis is somewhat controversial, it is clear that inflam-
matory signaling pathways are capable of driving a pro- fibrotic phe-
notype in lung fibroblasts.
6  |  PULMONARY­VIRAL­INFECTION­AND­
FIBROSIS
The development of pulmonary fibrosis is often reported as an im-
portant sequelae to severe or persistent lung damage including in 
patients with respiratory infections,49 connective tissue disorders 
108 and chronic granulomatous disease.109 Fibrosis is also a known 
sequelae of Acute Respiratory Distress Syndrome 110 and although 
many ARDS patients survive the acute phase of the illness, a sub-
stantial proportion of patients who have a longer disease duration 
(>3 weeks) will die as a result of progressive pulmonary fibrosis.111
Although a direct relationship between respiratory viral infec-
tion and development of progressive fibrosis has not been fully es-
tablished, evidence from the previous global SARS outbreaks with 
SARS- CoV and Middle East Respiratory Syndrome (MERS) shows a 
clear link between coronavirus infection, persistent impairment of 
lung function and abnormal radiological findings consistent with pul-
monary fibrosis.31- 33 Other respiratory viruses including Influenza 
H1N1 and H5N1 are also proposed to promote the development of 
pulmonary fibrosis 112- 115 while Hepatitis C, human cytomegalovirus 
and Epstein– Barr virus may act as viral cofactors in the development 
of IPF.116
The most extensive evidence of respiratory viral infection lead-
ing to fibrotic changes in the lung, is from a number of prospec-
tive studies of patients with Severe Acute Respiratory Syndrome 
(SARS) or Middle East Respiratory Syndrome (MERS). These re-
ports show that 30%- 60% of patients exhibit impairment of lung 
function following infection in addition to evidence of parenchymal 
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abnormalities.31- 33,117,118 Follow- up studies document that these 
lung abnormalities persist for many months postinfection with a 
gradual improvement in pulmonary function being seen over months 
to years in SARS patients.118,119
In the longest reported follow- up study, serial CT scans in 71 
SARS infected patients between 2003 and 2018 reveal parenchymal 
abnormalities including ground glass opacities and cord- like consoli-
dation in 27 patients (38%).120 Assessment of the percentage of lung 
area containing lesions over the 15- year period in these patients 
shows a significant reduction within the first 12 months after infec-
tion (from 9.40% in 2003 to 3.20% in 2004). However, the fibrotic 
changes persist and remain stable over subsequent years with le-
sions detected in 4.6% of the lung in 2018 with one patient exhibit-
ing obstructive lung disease.120
7  |  COVID-­19­INFECTION,­ARDS­AND­
FIBROSIS
Due to the rapid increase in fatalities following infection with SARS- 
CoV- 2, evidence of an association between viral infection and the 
development of pulmonary fibrosis in COVID- 19 patients appeared 
early in the pandemic with the degree of fibrotic change ranging 
from fibrosis in organizing pneumonia to widespread fibrotic dis-
ease following severe acute lung injury.121 The diagnosis of COVID- 
19- associated ARDS in patients with severe disease,24,122 evidence 
of extensive pulmonary interstitial fibrosis in explanted lungs 
from COVID- 19 patients receiving lung transplants for end- stage 
ARDS,123 and the presence of DAD, thickening of alveolar septa, 
proliferation of fibroblasts and evidence of fibrosis in other post-
mortem analyses confirmed this link.124- 128
In addition to the histological findings in postmortem 
COVID- 19 lung tissue, radiological evidence of fibrosis is seen in 
chest CT scans of both symptomatic and asymptomatic patients 
following SARS- CoV- 2 infection.128- 131 The key radiological fea-
tures of COVID- 19 infection are bilateral distribution of ground 
glass opacities (GGO) with or without consolidation in posterior 
and peripheral lungs.132 In early studies, the extent of lung ab-
normalities detected by CT scan showed a marked increase from 
the subclinical period (0- 7 days) through the first and second 
weeks after symptom onset before decreasing gradually into week 
three.128,130,131,133 These findings mirror the chronology of fibrosis 
detected in patients with ARDS.134
As previously seen with SARS and MERS, many COVID- 19 pa-
tients followed by serial CT imaging during hospitalization show sig-
nificant radiological improvement at the time of discharge. However, 
for a proportion of patients, radiologic deterioration is linked to a 
poor prognosis.128,135 Although it is still too early to determine 
whether the COVID19- associated fibrotic changes in the lung are 
irreversible, recent evidence confirms persistent functional and ra-
diological respiratory abnormalities at 4 months 136 and 6 months 137 
after severe COVID- 19 illness. In addition, a recent systematic re-
view and meta- analysis investigating the prevalence of radiological 
and functional consequences posthospitalization for viral pneumo-
nitis reports that although on follow- up, the inflammatory conse-
quences and features of fibrosis in COVID- 19 patients are reduced 
from baseline, fibrotic sequelae are still observed in a similar propor-
tion of people across different follow- up times. These data suggest 
that in SARSCoV2 infection as with SARS and MERS, the pulmonary 
fibrosis associated with viral pneumonitis does not resolve substan-
tially in the first year following infection.34
Although it is too early to determine whether COVID- 19 pa-
tients exhibiting significant lung abnormalities postinfection will 
ultimately develop stable, low levels of pulmonary fibrosis with 
relatively normal lung function as with SARS or MERS, or go on to 
develop progressive pulmonary fibrosis, it is likely that even long- 
term residual pulmonary fibrosis will result in significant morbidity 
particularly in older patients with other co- morbidities.138 Shojaee 
et al (2021) recently reported that in two retrospective observa-
tional cohort studies using longitudinal hospitalization records, 
viral pneumonia is associated with an increased risk of developing 
postinflammatory pulmonary fibrosis (PIPF) and that patients with 
a prior viral pneumonia diagnosis developed PIPF earlier and at a 
younger age.139 Given the scale of the global COVID- 19 pandemic, 
the number of people requiring invasive ventilation, and the de-
gree of lung injury in these patients, it is likely that the incidence 
of postviral fibrosis will increase substantially in the coming years. 
Understanding the mechanisms underlying COVID- 19 mediated 
lung fibrosis may therefore be key to developing targeted strat-





The airway epithelial layer is a pseudostratified mucosal barrier com-
prising several cell types, which acts as a barrier to many pathogens 
such as SARS- CoV- 2, MERS- CoV (Middle East respiratory syndrome- 
related coronavirus), and SARS- CoV.140 Although Angiotensin- 
converting enzyme 2 (ACE2) is reported to be the primary receptor 
for SARS- CoV- 2, its contribution to SARS- CoV- 2 infectivity is not well 
understood. Despite reports of very low levels of ACE2 expressing 
cells in the alveolar parenchyma SARS- CoV- 2 infection leads to sub-
stantial alveolar damage.141 In response to injury, including following 
viral infection, AT2 cells which are generally more injury- resistant 
migrate to the damaged area of lung, differentiate into AT1 type 
cells, and proliferate to promote re- epithelialization.142 Following 
alveolar epithelial cell injury, infiltration of fibroblasts and inflam-
matory cells leads to release and activation of pro- fibrotic mediators 
such as TGFβ and PDGF, resulting in matrix synthesis and accumula-
tion.143 In addition, the alveolar epithelium regulates production of 
urokinase and plasminogen activator inhibitor 1 (PAI1) and thereby 
controls the coagulation and fibrinolysis on the alveolar surface.144 
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Both hemorrhage and fibrin deposition in the alveolar space and mi-
crovasculature is reported to be associated SARS- CoV- 2 pathology 
implying the role of alveolar epithelium in promoting the coagulation 
disorders in COVID- 19.
TGF- β has been proposed as a potential therapeutic target in 
the treatment of COVID- 19 145 and previous studies suggest that 
epithelial TGF- β1 acts as a principal trigger regulating lung injury 
and fibrosis.53 Over expressing TGF- β1 in vivo results in progres-
sive pulmonary fibrosis 146 and TGF- β increases expression of the 
TGF- β activating integrin αvβ6.74 This upregulation of TGFβ through 
αvβ6 may suppress alveolar macrophage mediated type I inter-
feron responses and thereby increase the chance of a persistent 
viral infection.147 The SARS- CoV- 2 spike protein contains an RGD 
integrin- binding domain close to the ACE2 binding region, which 
could potentially facilitate binding to RGD- binding integrins,148 
which includes several TGF- β - activating integrins. Our recent data 
demonstrated that SARS- CoV- 2 is able to bind αvβ3 and αvβ6 inte-
grins to facilitate internalization into lung epithelial cells, which may 
be associated severe pathology associated COVID 19.20 These find-
ings suggest intriguing roles of lung epithelial cells involvement in 




As discussed previously, fibroblasts play a major role in tissue repair, 
following tissue injury fibroblasts proliferate and differentiate into 
myofibroblasts and they modulate extracellular matrix (ECM) vol-
ume. Myofibroblasts produce dense ECM compared to fibroblasts 
and having α- smooth muscle actin causes spatial reorganization of 
collagen fibrils, leading to stiffer ECM.50 As discussed above, TGF- β 
can regulate fibroblast proliferation,87,88 transdifferentiation to a 
contractile myofibroblast phenotype,89- 92 and can cause the pro-
duction and deposition of ECM proteins.87,93
Covid- 19 induced fibrotic changes in the lung may alter the bio-
mechanics of the lung resulting in lung tissue stiffening, similar to 
pulmonary fibrosis. Additionally, it has been suggested that SARS- 
CoV- 2 takes advantage of the altered mechanical properties ev-
ident in the aged lung that results from fibroblast dysfunction.149 
Cytoskeletal rearrangement plays a major role in promoting cell- cell 
spread of the virus.150 Furthermore, integrins, which are well known 
as a connecting link between the cytoskeleton and the ECM, can ac-
tivate fibroblasts, macrophage phagocytosis, modulate endothelial 
barrier function and can directly activate latent TGFβ induced pro- 
fibrotic pathways.151 Ultimately, stiffening of lung tissue will hinder 
gas exchange and eventually result in declining lung function, dys-
pnea, and exercise intolerance.
Finally, severe inflammation and the “cytokine storm”, has been 
proposed to be involved in COVID- 19 pathogenesis,152 although 
this continues to be a subject of controversy 153 and the relative im-
portance of inflammatory cytokines in COVID- 19 is still unclear.154 
While recent work has shown that cytokine levels in severe case of 
COVID- 19 are lower than those associated with ARDS unrelated 
to COVID- 19, sepsis and chimeric antigen receptor (CAR) T- cell in-
duced cytokine release syndrome, elevated levels of a number of 
inflammatory markers, particularly IL6, in severe cases of COVID- 19 
are found to predict the need for mechanical ventilation.155- 157 A 
number of randomized, controlled trials have reported the use of 
monoclonal antibodies that inhibit both membrane- bound and sol-
uble IL6 receptors in COVID- 19 patients with mixed results as they 
also included less severely ill patients and excluded patients receiv-
ing respiratory support.158- 163 The most recent of these, REMAP- 
CAP, reported improved outcomes, including survival, in critically ill 
adult COVID- 19 patients who were receiving organ support in ICUs 
at the time of treatment with the interleukin- 6 receptor antagonists 
tocilizumab and sarilumab.164 As discussed earlier in this article, in-
flammatory cytokines including IL6 can have a profound effect on 
the pro- fibrotic actions of fibroblasts.101- 103,105- 107 As a result, IL6 
may play a crucial role in the development of fibrotic changes in the 
lungs of COVID- 19 patients, in addition to its potential role in the 
acute phase response to infection.
The clearest evidence of a role of severe inflammation in 
COVID- 19 pathogenesis derives from the RECOVERY trial which 
demonstrated that treatment of hospitalized COVID- 19 patients 
with the potent anti- inflammatory corticosteroid, dexamethasone, 
results in a significant reduction in 28- day mortality 165 data sub-
sequently supported by three other trials.166- 168 Interestingly, dexa-
methasone treatment is also found to be beneficial only in patients 
receiving invasive mechanical ventilation or receiving oxygen with-
out invasive mechanical ventilation with no evidence of benefit 
among patients who were not receiving respiratory support. It re-
mains to be seen whether therapeutic strategies designed to limit 
inflammation generally, or IL6 specifically, might be beneficial in lim-
iting the fibrogenic response in severe COVID- 19, and whether early 
intervention will prevent the development of persistent interstitial 
fibrosis which characterized previous SARS and MERS pandemics.
There is now clear emerging evidence that COVID- 19 can lead 
to fibrotic changes in the lungs and in this review we have tried to 
bring together the existing knowledge of potential mechanisms that 
might link initial infection to the development of lung tissue remod-
eling. We have summarized this knowledge and tried to illustrate the 
potential interplay between pathways discussed above in Figure 1. 
There are numerous potential ways in which SARS- CoV- 2 might pro-
mote fibrogenesis including activation of inflammatory pathways, in-
jury to the alveolar epithelium and vascular changes. More research 
is desperately needed to fully delineate the underlying pathogenic 
mechanisms that drive COVID- 19- induced lung fibrosis.
10  |  PULMONARY­FIBROSIS­IN­COVID-­19:­
STABLE­OR­PROGRESSIVE?
One year in to the COVID- 19 pandemic, there is mounting evidence 
to suggest that many COVID- 19 patients develop fibrotic sequelae 
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and alterations in their lung function indicative of restrictive lung 
disease.29,34,121,123- 128 It is still too early to know whether such 
changes occur purely as a transient response to viral infection and 
will spontaneously resolve with time, however, data collected thus 
far suggests that fibrosis persists for many months after the infec-
tion has resolved.34,136,137 A crucial question in the management and 
treatment of such patients in the years to come is whether post- 
COVID- 19 fibrotic changes in the lung are stable once they have 
developed or are progressive, as in fibrotic lung diseases such as IPF.
There are many factors that might impact whether post- 
COVID- 19 lung fibrosis has the potential to become progressive and 
life- limiting. Genetics is likely to play a fundamental role. Genetic 
studies have highlighted genes involved with innate antiviral de-
fenses, inflammatory lung injury and the ABO blood- group system 
are associated with life- threatening COVID- 19.169,170 While no stud-
ies to date have studied genetic associations with post- COVID- 19 
fibrosis specifically, genome- wide association studies have high-
lighted numerous genes associated with the development of pulmo-
nary fibrosis.42- 44 This raises the possibility that COVID- 19 infection 
in individuals with genetic alterations known to be associated with 
the development of lung fibrosis may result in a more progressive 
post- COVID- 19 fibrosis. Prospective genome- wide studies of in-
dividuals that develop fibrotic lung sequelae following COVID- 19 
infection will shed light on the role that genetics plays in driving pro-
gressive or stable post- COVID- 19 fibrosis.
Increased age is a key risk factor for both pulmonary fibro-
sis and COVID- 19,6,171- 174 and could therefore be a contributing 
factor in whether post- COVID- 19 fibrosis becomes progressive. 
Increased age is associated with stiffening of the lung paren-
chyma,175,176 which could have important implications for TGFβ 
activation and the development of lung fibrosis.53 Age also affects 
the pro- fibrotic potential of lung fibroblasts. Fibroblasts isolated 
F IGURE ­1 Proposed mechanism of SARS- CoV- 2- associated fibrosis in the lung. INFECTION with SARS- CoV- 2 causes damage to the 
alveolar epithelium and induces production of epithelial and macrophage derived inflammatory and immune cytokines leading to lung 
INJURY. Activated inflammatory cells and damaged epithelial cells contribute to the denudation of the basement membrane leading to 
migration and proliferation of interstitial fibroblasts in the alveolar space in response to TGFb, PDGF and IL- 6. SARS- CoV- 2 infection also 
injures endothelial cells resulting in hemorrhage and leakage of plasma into the alveolus. In response to urokinase and PAI- 1 release from the 
damaged alveolar epithelium, coagulation pathways are activated leading to fibrin deposition. Persistent alveolar activation of TGFb, release 
of PDGF and IL- 6 from alveolar epithelia cells, immune cells and myofibroblasts leads to proliferation of myofibroblasts and development of 
FIBROSIS
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from aged mice have reduced Thy- 1 expression, which is associ-
ated with a pro- fibrotic phenotype,177,178 plus reduced apoptosis 
and increased responses to TGFβ.179 Furthermore, culturing fibro-
blasts and lung epithelial cells on decellularized aged ECM leads to 
alterations in the composition of ECM deposited by the cells.180 
Crucially, viral- induced lung injury results in exacerbated lung fi-
brosis in aged mice.181- 183 The role that increased age plays in the 
development and progression of COVID- 19- associated fibrotic 
changes requires further study.
Obesity and metabolic syndrome are common risk factors for 
COVID- 19.7,184,185 Both type 1 and type 2 diabetes are associated 
with significantly increased risk of mortality from COVID- 19.184,186 
Similarly, patients with pulmonary fibrosis are often overweight 187,188 
and are more like to present with a clinical history of hypertension 
or diabetes, suggestive of metabolic syndrome.189 Furthermore, in-
creased body mass index (BMI) is associated with a increased risk of 
developing ARDS in at- risk patients.190 While direct evidence show-
ing that obesity and/or alterations in metabolism contributes to fibro-
genesis in COVID- 19 is lacking, there are several studies suggesting 
a mechanistic link with pulmonary fibrosis.181,191- 193 At a cellular level 
interrupting the signaling of peroxisome proliferator activated recep-
tor gamma co- activator 1- alpha (PGC1α), a transcriptional co- activator 
with important roles in regulating metabolism, enhances the contrac-
tility of fibroblasts and causes them to deposit greater amounts of 
collagen I and fibronectin.194 Similarly, reduced expression of PTEN, a 
protein that controls the metabolism of glucose and fatty acids, causes 
fibroblast- myofibroblasts transdifferentiation and collagen produc-
tion.195 Moreover, the anti- diabetic drug Metformin can inhibit TGFβ- 
induced fibrotic responses in lung fibroblasts in vitro and accelerate 
the resolution of experimental pulmonary fibrosis.196 Importantly, 
Metformin is associated with reduced mortality in COVID- 19 patients, 
particularly in women.197,198 This supports the hypothesis that meta-
bolic alterations are involved in COVID- 19 pathogenesis, however, the 
relative role of such alterations in driving either stable or progressive 
fibrosis requires further research.
11  |  CONCLUDING­REMARKS
While viral infection can cause viral- induced fibrosis 116 a clear as-
sociation between viral infection and progressive fibrosis is still 
unclear. There is mounting evidence that fibrotic changes and in-
terstitial lung abnormalities may result from COVID- 19 infection 
in some cases, however, how these changes develop and whether 
the fibrosis is stable or progressive is unknown. More research is 
urgently needed to (a) confirm that COVID- 19 can result in fibrotic 
lung disease, (b) establish the prevalence and epidemiology of such 
changes, and (c) delineate the cellular and molecular mechanisms 
driving fibrotic changes following SARS- CoV- 2 infection. Through 
drawing on the vast existing literature from the field of pulmonary 
fibrosis we hypothesize that such fibrotic changes will involve both 
epithelial and fibroblast- mediated mechanisms. Furthermore, our 
knowledge of the mechanisms underpinning lung fibrosis suggests 
that genetics, age and metabolic alterations may all play a role in 
driving the fibrotic phenotype and ultimately the long- term outcome 
for post- COVID- 19 lung fibrosis.
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